<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00614549</url>
  </required_header>
  <id_info>
    <org_study_id>N01283</org_study_id>
    <nct_id>NCT00614549</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Levetiracetam in Routine Clinical Practice in Czech and Slovak Republics, Hungary, and Romania.</brief_title>
  <official_title>Long-term Evaluation of the Efficacy and Safety of Levetiracetam in Routine Clinical Practice in the Czech and Slovak Republics, Hungary, and Romania - Non-interventional Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UCB Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UCB Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate, over 1 year period, the efficacy and safety of newly prescribed levetiracetam as
      add-on treatment (POS, myoclonoc seizures in JME and PGTCS in IGE) or primary monotherapy
      (partial onset seizures) in adult and paediatric patients within the approved age limits in
      routine clinical practice in Czech and Slovak Republics, Hungary, and Romania.
      Non-interventional study.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2007</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Retention rate after 6 and 12 months</measure>
    <time_frame>6 and 12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Seizure freedom for the last 6 and 12 months</measure>
    <time_frame>6 and 12 months</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">2569</enrollment>
  <condition>Epilepsy</condition>
  <arm_group>
    <arm_group_label>Levetiracetam</arm_group_label>
    <description>Patients treated with Levetiracetam</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Primary care clinics and hospitals.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  diagnoses of partial onset seizures (POS) with or without secondary generalisation or
             Juvenile Myoclonic Epilepsy (JME) or another IGE with PGTCS

          -  newly prescribed levetiracetam as add-on treatment (POS, myoclonic seizures in JME and
             PGTCS in IGE) or monotherapy (partial onset seizures only) in newly diagnosed
             patients. Newly prescribed means inclusion of the patients in whom a decision has been
             made to prescribe LEV and the first dose is just to be prescribed.

          -  age 4 years or above for partial onset seizures, 12 years or above for MS in JME or
             PGTCS in IGE, 16 years or above for monotherapy

          -  patient written informed consent

        Exclusion Criteria:

          -  indications other than those defined in inclusion criteria

          -  history of allergic or anaphylactic reactions to levetiracetam or other pyrrolidone
             derivatives and excipients included
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>UCB Clinical Trial Call Center</last_name>
    <role>Study Director</role>
    <affiliation>+1 877 822 9493 (UCB)</affiliation>
  </overall_official>
  <removed_countries>
    <country>Slovakia</country>
    <country>United States</country>
  </removed_countries>
  <verification_date>May 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 11, 2008</study_first_submitted>
  <study_first_submitted_qc>January 30, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 13, 2008</study_first_posted>
  <last_update_submitted>May 25, 2012</last_update_submitted>
  <last_update_submitted_qc>May 25, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 28, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Levetiracetam</keyword>
  <keyword>Keppra</keyword>
  <keyword>Epilepsy</keyword>
  <keyword>Efficacy</keyword>
  <keyword>Safety</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epilepsy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etiracetam</mesh_term>
    <mesh_term>Piracetam</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

